Bionano Genomics (BNGO) Total Liabilities (2017 - 2026)

Bionano Genomics has disclosed Total Liabilities across 10 years of filings, most recently posting $27.3 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $27.3 million, down 9.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.3 million (down 9.54% YoY), and the FY2025 annual result was $29.2 million, down 29.39% from the prior year.
• Total Liabilities came in at $27.3 million for Q1 2026 at Bionano Genomics, down from $29.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $118.2 million in Q4 2023 to a low of $27.3 million in Q1 2026.
• The 5-year median for Total Liabilities is $41.3 million (2024), against an average of $48.4 million.
• Across the five-year window, Total Liabilities jumped 236.45% in 2022 and plunged 65.08% in 2024, its largest moves.
• Bionano Genomics' Total Liabilities stood at $58.1 million in 2022, then soared by 103.51% to $118.2 million in 2023, then slumped by 65.08% to $41.3 million in 2024, then retreated by 29.39% to $29.2 million in 2025, then declined by 6.24% to $27.3 million in 2026.
• The last three Total Liabilities figures came in at $27.3 million (Q1 2026), $29.2 million (Q4 2025), and $29.3 million (Q3 2025), per Business Quant data.